• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A closer look at the mysterious HSD17B13.

作者信息

Dong X Charlie

机构信息

Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA

出版信息

J Lipid Res. 2020 Nov;61(11):1361-1362. doi: 10.1194/jlr.C120001160. Epub 2020 Oct 2.

DOI:10.1194/jlr.C120001160
PMID:33008926
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7604724/
Abstract
摘要

相似文献

1
A closer look at the mysterious HSD17B13.深入探究神秘的17β-羟类固醇脱氢酶13（HSD17B13）。
J Lipid Res. 2020 Nov;61(11):1361-1362. doi: 10.1194/jlr.C120001160. Epub 2020 Oct 2.
2
HCV-Associated Liver Fibrosis and HSD17B13.丙型肝炎病毒相关肝纤维化与17β-羟基类固醇脱氢酶13
N Engl J Med. 2018 Nov 8;379(19):1875-1876. doi: 10.1056/NEJMc1804638.
3
SERPINA1 and HSD17B13 Gene Variants in Patients with Liver Fibrosis and Cirrhosis.丝氨酸蛋白酶抑制剂 A1 基因和 17β-羟类固醇脱氢酶 13 基因变异与肝纤维化和肝硬化患者的关系。
J Gastrointestin Liver Dis. 2019 Sep 12;28(3):297-302. doi: 10.15403/jgld-168.
4
Role of HSD17B13 in the liver physiology and pathophysiology.HSD17B13 在肝脏生理学和病理生理学中的作用。
Mol Cell Endocrinol. 2019 Jun 1;489:119-125. doi: 10.1016/j.mce.2018.10.014. Epub 2018 Oct 24.
5
Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers.HSD17B13 基因变异可降低酒精滥用者发生肝硬化和肝细胞癌的风险。
Hepatology. 2020 Jul;72(1):88-102. doi: 10.1002/hep.30996. Epub 2020 May 20.
6
17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma.17-β-羟类固醇脱氢酶 13 抑制肝细胞癌的进展和复发。
Hepatobiliary Pancreat Dis Int. 2018 Jun;17(3):220-226. doi: 10.1016/j.hbpd.2018.04.006. Epub 2018 Apr 22.
7
HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.HSD17B13 rs72613567 可预防肝脏疾病和非酒精性脂肪性肝病的组织学进展：系统评价和荟萃分析。
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8997-9007. doi: 10.26355/eurrev_202009_22842.
8
Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity.鉴定 HSD17B13 中与细胞定位和酶活性相关的必需结构域。
J Lipid Res. 2020 Nov;61(11):1400-1409. doi: 10.1194/jlr.RA120000907. Epub 2020 Sep 24.
9
High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.HSD17B13 变异可增加脂肪肝疾病风险并降低丙氨酸氨基转移酶。
Hepatology. 2020 Jan;71(1):56-66. doi: 10.1002/hep.30799. Epub 2019 Aug 9.
10
The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.经活检证实的非酒精性脂肪性肝病患者中，HSD17B13基因rs72613567变异与较低水平的蛋白尿相关。
Nutr Metab Cardiovasc Dis. 2021 Jun 7;31(6):1822-1831. doi: 10.1016/j.numecd.2021.02.018. Epub 2021 Feb 25.

引用本文的文献

1
HSD17B13 liquid-liquid phase separation promotes leukocyte adhesion in chronic liver inflammation.17β-羟基类固醇脱氢酶13（HSD17B13）的液-液相分离促进慢性肝脏炎症中的白细胞黏附。
J Mol Cell Biol. 2024 Nov 25;16(6). doi: 10.1093/jmcb/mjae018.
2
Emerging roles of RNA-binding proteins in fatty liver disease.RNA 结合蛋白在脂肪性肝病中的新兴作用。
Wiley Interdiscip Rev RNA. 2024 Mar-Apr;15(2):e1840. doi: 10.1002/wrna.1840.
3
17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population.17-β-羟基类固醇脱氢酶13功能丧失对印度人群非酒精性脂肪性肝病无保护作用。
J Clin Exp Hepatol. 2024 Jul-Aug;14(4):101371. doi: 10.1016/j.jceh.2024.101371. Epub 2024 Feb 19.
4
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond.探索代谢相关脂肪性肝病的多维度图景：从病理生理学到类器官及其他领域的近期研究综合概述
Biomedicines. 2024 Feb 8;12(2):397. doi: 10.3390/biomedicines12020397.
5
Drug development advances in human genetics-based targets.基于人类遗传学靶点的药物研发进展。
MedComm (2020). 2024 Feb 9;5(2):e481. doi: 10.1002/mco2.481. eCollection 2024 Feb.
6
The Influence of the FFAR4 Agonist TUG-891 on Liver Steatosis in ApoE-Knockout Mice.FFAR4 激动剂 TUG-891 对载脂蛋白 E 基因敲除小鼠肝脂肪变性的影响。
Cardiovasc Drugs Ther. 2024 Aug;38(4):667-678. doi: 10.1007/s10557-023-07430-7. Epub 2023 Jan 27.
7
Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions.从儿童期到成年期的代谢相关脂肪性肝病：现状与未来方向。
World J Hepatol. 2022 Jun 27;14(6):1087-1098. doi: 10.4254/wjh.v14.i6.1087.
8
Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.小儿非酒精性脂肪性肝病的进展：从遗传学到脂质组学。
World J Clin Pediatr. 2022 Mar 23;11(3):221-238. doi: 10.5409/wjcp.v11.i3.221. eCollection 2022 May 9.
9
Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis.从非酒精性脂肪性肝病到肝纤维化过程中肝损伤中肝细胞与非实质细胞的病理生理学通讯。
Adv Drug Deliv Rev. 2021 Sep;176:113869. doi: 10.1016/j.addr.2021.113869. Epub 2021 Jul 16.

本文引用的文献

1
17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.17-β 羟甾体脱氢酶 13 缺乏症不能保护小鼠免受致肥胖饮食的损伤。
Hepatology. 2021 May;73(5):1701-1716. doi: 10.1002/hep.31517. Epub 2021 Mar 16.
2
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort.全基因组关联研究非酒精性脂肪肝和肝脂肪性肝炎在组织学特征化队列中。
J Hepatol. 2020 Sep;73(3):505-515. doi: 10.1016/j.jhep.2020.04.003. Epub 2020 Apr 13.
3
Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.羟基类固醇17-β脱氢酶13变体增加磷脂并预防非酒精性脂肪性肝病中的纤维化。
JCI Insight. 2020 Mar 12;5(5):132158. doi: 10.1172/jci.insight.132158.
4
Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers.HSD17B13 基因变异可降低酒精滥用者发生肝硬化和肝细胞癌的风险。
Hepatology. 2020 Jul;72(1):88-102. doi: 10.1002/hep.30996. Epub 2020 May 20.
5
High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.HSD17B13 变异可增加脂肪肝疾病风险并降低丙氨酸氨基转移酶。
Hepatology. 2020 Jan;71(1):56-66. doi: 10.1002/hep.30799. Epub 2019 Aug 9.
6
A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.17β-羟甾体脱氢酶 13 变体可预防酒精性肝病中的肝细胞癌发展。
Hepatology. 2019 Jul;70(1):231-240. doi: 10.1002/hep.30623. Epub 2019 Apr 25.
7
17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.17-β 羟甾类脱氢酶 13 是一种与非酒精性脂肪性肝病组织学特征相关的肝视黄醇脱氢酶。
Hepatology. 2019 Apr;69(4):1504-1519. doi: 10.1002/hep.30350. Epub 2019 Mar 5.
8
HCV-Associated Liver Fibrosis and HSD17B13.丙型肝炎病毒相关肝纤维化与17β-羟基类固醇脱氢酶13
N Engl J Med. 2018 Nov 8;379(19):1875-1876. doi: 10.1056/NEJMc1804638.
9
HSD17B13 and Chronic Liver Disease in Blacks and Hispanics.HSD17B13与黑人和西班牙裔人群的慢性肝病
N Engl J Med. 2018 Nov 8;379(19):1876-1877. doi: 10.1056/NEJMc1804027.
10
Role of HSD17B13 in the liver physiology and pathophysiology.HSD17B13 在肝脏生理学和病理生理学中的作用。
Mol Cell Endocrinol. 2019 Jun 1;489:119-125. doi: 10.1016/j.mce.2018.10.014. Epub 2018 Oct 24.